Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KDM6B | O15054 | 3/20 | 0.55 |
| ▸ | KDM5C | P41229 | 3/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.55 |
| ▸ | KDM4A | O75164 | 2/20 | 0.55 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | KDM5A | P29375 | 2/20 | 0.55 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095006 | 0.87 | KDM4C (0.53) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL16094544 | 0.87 | KDM4C (0.53) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL30069005 | 0.87 | KDM4C (0.53) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL16036217 | 0.85 | KDM4C (0.52) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL30893039 | 0.85 | KDM4C (0.52) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL10202654 | 0.85 | LMNA (0.58) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL31085231 | 0.85 | LMNA (0.58) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL11347447 | 0.83 | LMNA (0.56) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL25701470 | 0.82 | KDM4C (0.51) | LMNASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL25340658 | 0.81 | KDM4C (0.47) | LMNASMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117343005-A | Preparation method of isonicotinic acid derivative | 上海泰坦科技股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-1615919-B1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| CN-1774437-A | 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | CN | disclosed |
| EP-1615919-A1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-6872833-B2 | Adenosine receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2004089949-A1 | 7-([1,4]DIOXAN-2-YL)-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| EP-0862555-B1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-14 | — | — | US | disclosed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | LMNA 42/4885SMN1; SMN2 126/4885NPC1 4666/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | LMNA 1164/4885SMN1; SMN2 3197/4885NPC1 285/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | LMNA 1164/4885SMN1; SMN2 3197/4885NPC1 285/4885 |
| US-20040204584-A1 | ADENOSINE RECEPTOR LIGANDS | ADORA1, ADORA2A, ADORA3 | LMNA 3437/4885SMN1; SMN2 3519/4885NPC1 1169/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | LMNA 2740/4885SMN1; SMN2 1897/4885NPC1 1080/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | LMNA 1164/4885SMN1; SMN2 3197/4885NPC1 285/4885 |
| US-20110112080-A1 | OXAZOLINE DERIVATIVES | TAAR1, HCRTR1, NPY1R | LMNA 3754/4885SMN1; SMN2 2163/4885NPC1 785/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | LMNA 3911/4885SMN1; SMN2 3190/4885NPC1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.